A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

NCT06310746 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

IPF

Interventions

DRUG: GARP/TGF-β1 monoclonal antibody
DRUG: Placebo

Sponsor

Shanghai Henlius Biotech